Top

Published in:

Open Access 01-12-2024 | Alzheimer's Disease | Research

Prevalence, distribution, and severity of cerebral amyloid angiopathy differ between Lewy body diseases and Alzheimer’s disease

Authors: Lauren Walker, Harry Simpson, Alan J. Thomas, Johannes Attems

Published in: Acta Neuropathologica Communications | Issue 1/2024

Abstract

Dementia with Lewy bodies (DLB), Parkinson’s disease dementia (PDD), and Parkinson’s disease (PD) collectively known as Lewy body diseases (LBDs) are neuropathologically characterised by α-synuclein deposits (Lewy bodies and Lewy neurites). However, LBDs also exhibit pathology associated with Alzheimer’s disease (AD) (i.e. hyperphosphorylated tau and amyloid β (Aβ). Aβ can be deposited in the walls of blood vessels in the brains of individuals with AD, termed cerebral amyloid angiopathy (CAA). The aim of this study was to investigate the type and distribution of CAA in DLB, PDD, and PD and determine if this differs from AD. CAA type, severity, and topographical distribution was assessed in 94 AD, 30 DLB, 17 PDD, and 11 PD cases, and APOE genotype evaluated in a subset of cases where available. 96.3% AD cases, 70% DLB cases and 82.4% PDD cases exhibited CAA (type 1 or type 2). However only 45.5% PD cases had CAA. Type 1 CAA accounted for 37.2% of AD cases, 10% of DLB cases, and 5.9% of PDD cases, and was not observed in PD cases. There was a hierarchical topographical distribution in regions affected by CAA where AD and DLB displayed the same distribution pattern that differed from PDD and PD. APOE ε4 was associated with severity of CAA in AD cases. Topographical patterns and severity of CAA in DLB more closely resembled AD rather than PDD, and as type 1 CAA is associated with clinical dementia in AD, further investigations are warranted into whether the increased presence of type 1 CAA in DLB compared to PDD are related to the onset of cognitive symptoms and is a distinguishing factor between LBDs. Possible alignment of the the topographical distribution of CAA and microbleeds in DLB warrants further investigation. CAA in DLB more closely resembles AD rather than PDD or PD, and should be taken into consideration when stratifying patients for clinical trials or designing disease modifying therapies.

Available only for authorised users

Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H et al (2008) Staging of neurofibrillary pathology in Alzheimer’s disease: a study of the BrainNet Europe Consortium. Brain Pathol 18(4):484A496. https://doi.org/10.1111/j.1750-3639.2008.00147.xCrossRefPubMedPubMedCentral

Arvanitakis Z, Leurgans SE, Wang Z, Wilson RS, Bennett DA, Schneider JA (2011) Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann Neurol 69(2):320A327. https://doi.org/10.1002/ana.22112CrossRefPubMed

Attems J (2005) Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol 110(4):345A359. https://doi.org/10.1007/s00401-005-1074-9CrossRefPubMed

Attems J, Jellinger KA (2004) Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathologyAa pilot study. Acta Neuropathol 107(2):83A90. https://doi.org/10.1007/s00401-003-0796-9CrossRefPubMed

Attems J, Jellinger KA, Lintner F (2005) Alzheimer’s disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol 110(3):222A231. https://doi.org/10.1007/s00401-005-1064-yCrossRefPubMed

Badiola N, de Oliveira RM, Herrera F, Guardia-Laguarta C, Goncalves SA, Pera M et al (2011) Tau enhances alpha-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS ONE 6(10):e26609. https://doi.org/10.1371/journal.pone.0026609CrossRefPubMedPubMedCentralADS

Boyle PA, Yu L, Nag S, Leurgans S, Wilson RS, Bennett DA, Schneider JA (2015) Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology 85(22):1930A1936. https://doi.org/10.1212/WNL.0000000000002175CrossRefPubMedPubMedCentral

Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112(4):389A404. https://doi.org/10.1007/s00401-006-0127-zCrossRefPubMedPubMedCentral

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197A211. https://doi.org/10.1016/s0197-4580(02)00065-9CrossRefPubMed

10.

Brayne C, Richardson K, Matthews FE, Fleming J, Hunter S, Xuereb JH et al (2009) Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based cambridge city over-75s cohort (CC75C) study. J Alzheimer’s Dis 18:645A658. https://doi.org/10.3233/JAD-2009-1182CrossRef

11.

Cadavid D, Mena H, Koeller K, Frommelt RA (2000) Cerebral beta amyloid angiopathy is a risk factor for cerebral ischemic infarction. A case control study in human brain biopsies. J Neuropathol Exp Neurol 59(9):768A773. https://doi.org/10.1093/jnen/59.9.768CrossRefPubMed

12.

Case NF, Charlton A, Zwiers A, Batool S, McCreary CR, Hogan DB et al (2016) Cerebral amyloid angiopathy is associated with executive dysfunction and mild cognitive impairment. Stroke 47(8):2010A2016. https://doi.org/10.1161/strokeaha.116.012999CrossRefPubMed

13.

Ciaccioli G, Martins A, Rodrigues C, Vieira H, Calado P (2013) A powerful yeast model to investigate the synergistic interaction of alpha-synuclein and tau in neurodegeneration. PLoS ONE 8(2):e55848. https://doi.org/10.1371/journal.pone.0055848CrossRefPubMedPubMedCentralADS

14.

Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM (2010) Synergistic interactions between abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 30(21):7281A7289. https://doi.org/10.1523/jneurosci.0490-10.2010CrossRefPubMedPubMedCentral

15.

Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261(5123):921A923. https://doi.org/10.1126/science.8346443CrossRefPubMedADS

16.

Donaghy PC, Firbank M, Mitra D, Petrides G, Lloyd J, Barnett N et al (2020) Microbleeds in dementia with Lewy bodies. J Neurol 267(5):1491A1498. https://doi.org/10.1007/s00415-020-09736-0CrossRefPubMedPubMedCentral

17.

Dugger BN, Adler CH, Shill HA, Caviness J, Jacobson S, Driver-Dunckley E, Beach TG (2014) Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord 20(5):525A529. https://doi.org/10.1016/j.parkreldis.2014.02.012CrossRefPubMedPubMedCentral

18.

Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N et al (2008) Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79(12):1331A1338. https://doi.org/10.1136/jnnp.2007.127878CrossRefPubMed

19.

Frings L, Hellwig S, Spehl TS, Bormann T, Buchert R, Vach W et al (2015) Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer’s disease. Brain 138(10):3089A3099. https://doi.org/10.1093/brain/awv229CrossRefPubMed

20.

Geinisman RV, Oksova EE (1988) Morphologic diagnosis of vascular and senile dementia (the significance of Congophilic angiopathy). Zh Nevropatol Psikhiatr Im S S Korsakova 88(7):35A39PubMed

21.

Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT et al (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300(5619):636A640. https://doi.org/10.1126/science.1082324CrossRefPubMedADS

22.

Greenberg SM, Vonsattel JP, Segal AZ, Chiu RI, Clatworthy AE, Liao A et al (1998) Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology 50(4):961A965. https://doi.org/10.1212/wnl.50.4.961CrossRefPubMed

23.

Gungor I, Sarro L, Graff-Radford J, Zuk SM, Tosakulwong N, Przybelski SA et al (2015) Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer’s disease. Parkinsonism Relat Disord 21(9):1101A1104. https://doi.org/10.1016/j.parkreldis.2015.07.008CrossRefPubMedPubMedCentral

24.

Halliday GM, Song YJ, Harding AJ (2011) Striatal beta-amyloid in dementia with Lewy bodies but not Parkinson’s disease. J Neural Transm 118(5):713A719. https://doi.org/10.1007/s00702-011-0641-6CrossRefPubMed

25.

Hansen D, Ling H, Lashley T, Foley J, Strand C, Eid T et al (2021) Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson’s disease dementia. Neuropathol Appl Neurobiol 47(1):143A156. https://doi.org/10.1111/nan.12648CrossRefPubMed

26.

Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL et al (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14(4):388A405. https://doi.org/10.1016/s1474-4422(15)70016-5CrossRefPubMedPubMedCentral

27.

Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX et al (2017) Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol 16(1):55A65. https://doi.org/10.1016/s1474-4422(16)30291-5CrossRefPubMedPubMedCentral

28.

Jellinger KA (2002) Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 109(5A6):813A836. https://doi.org/10.1007/s007020200068CrossRefPubMed

29.

Jellinger KA (2021) Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases. J Neural Transm 128(5):687A699. https://doi.org/10.1007/s00702-021-02345-9CrossRefPubMed

30.

Jellinger KA, Attems J (2008) Cerebral amyloid angiopathy in Lewy body disease. J Neural Transm (Vienna) 115(3):473A482. https://doi.org/10.1007/s00702-007-0856-8CrossRefPubMed

31.

Jellinger KA, Attems J (2006) Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol 112(3):253A260. https://doi.org/10.1007/s00401-006-0088-2CrossRefPubMed

32.

Joachim CL, Morris JH, Selkoe DJ (1988) Clinically diagnosed Alzheimer’s disease: autopsy results in 150 cases. Ann Neurol 24(1):50A56. https://doi.org/10.1002/ana.410240110CrossRefPubMed

33.

Kim SW, Chung SJ, Oh YS, Yoon JH, Sunwoo MK, Hong JY et al (2015) Cerebral microbleeds in patients with dementia with lewy bodies and parkinson disease dementia. AJNR Am J Neuroradiol 36(9):1642A1647. https://doi.org/10.3174/ajnr.A4337CrossRefPubMedPubMedCentral

34.

King A, Bodi I, Nolan M, Troakes C, Al-Sarraj S (2015) Assessment of the degree of asymmetry of pathological features in neurodegenerative diseases. What is the significance for brain banks? J Neural Transm 122(10):1499A1508. https://doi.org/10.1007/s00702-015-1410-8CrossRefPubMed

35.

Kovacs GG, Alafuzoff I, Al-Sarraj S, Arzberger T, Bogdanovic N, Capellari S et al (2008) Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord 26(4):343A350. https://doi.org/10.1159/000161560CrossRefPubMed

36.

Love S, Chalmers K, Ince P, Esiri M, Attems J, Jellinger K et al (2014) Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am J Neurodegener Dis 3(1):19A32PubMedPubMedCentral

37.

Mäkelä M, Paetau A, Polvikoski T, Myllykangas L, Tanskanen M (2016) Capillary amyloid-β protein deposition in a population-based study (Vantaa 85+). J Alzheimer’s Dis 49(1):149A157. https://doi.org/10.3233/jad-150241CrossRef

38.

Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P (2009) Epidemiological pathology of dementia: attributable-risks at death in the medical research council cognitive function and ageing study. PLoS Med 6(11):e1000180. https://doi.org/10.1371/journal.pmed.1000180CrossRefPubMedPubMedCentral

39.

McAleese K, Walker L, Erskine D, Johnson M, Koss D, Thomas A, Attems J (2020) Concomitant LATE-NC in Alzheimer’s disease is not associated with increased tau or amyloid-β pathological burden. Neuropathol Appl Neurobiol 46(7):722A734. https://doi.org/10.1111/nan.12664CrossRefPubMed

40.

McAleese KE, Colloby SJ, Thomas AJ, Al-Sarraj S, Ansorge O, Neal J et al (2021) Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia. Alzheimer’s Dement 17(7):1121A1133. https://doi.org/10.1002/alz.12291CrossRef

41.

McCarron MO, Nicoll JAR, Stewart J, Ironside JW, Mann DMA, Love S et al (1999) The apolipoprotein E ∈2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. J Neuropathol Exp Neurol 58(7):711A718. https://doi.org/10.1097/00005072-199907000-00005CrossRefPubMed

42.

McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89(1):88A100. https://doi.org/10.1212/wnl.0000000000004058CrossRefPubMedPubMedCentral

43.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 34(7):939A944. https://doi.org/10.1212/wnl.34.7.939CrossRefPubMed

44.

Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM et al (1991) The consortium to establish a registry for Alzheimer’s disease (CERAD) Part II standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41(4):479A486. https://doi.org/10.1212/wnl.41.4.479CrossRefPubMed

45.

Montine T, Phelps C, Beach T, Bigio E, Cairns N, Dickson D et al (2012) National institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 123:1A11. https://doi.org/10.1007/s00401-011-0910-3CrossRefPubMed

46.

Nicoll JAR, Burnett C, Love S, Graham DI, Dewar D, Ironside JW et al (1997) High frequency of apolipoprotein E ϵ2 Allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol 41(6):716A721. https://doi.org/10.1002/ana.410410607CrossRefPubMed

47.

Olichney JM, Hansen LA, Hofstetter CR, Grundman M, Katzman R, Thal LJ (1995) Cerebral infarction in Alzheimer’s disease is associated with severe amyloid angiopathy and hypertension. Arch Neurol 52(7):702A708. https://doi.org/10.1001/archneur.1995.00540310076019CrossRefPubMed

48.

Parker JC Jr, Philpot J (1985) Postmortem evaluation of Alzheimer’s disease. South Med J 78(12):1411A1413. https://doi.org/10.1097/00007611-198512000-00003CrossRefPubMed

49.

Preston SD, Steart PV, Wilkinson A, Nicoll JA, Weller RO (2003) Capillary and arterial cerebral amyloid angiopathy in Alzheimer’s disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol Appl Neurobiol 29(2):106A117. https://doi.org/10.1046/j.1365-2990.2003.00424.xCrossRefPubMed

50.

Soontornniyomkij V, Lynch MD, Mermash S, Pomakian J, Badkoobehi H, Clare R, Vinters HV (2010) Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy. Brain Pathol 20(2):459A467. https://doi.org/10.1111/j.1750-3639.2009.00322.xCrossRefPubMed

51.

Stefanits H, Budka H, Kovacs GG (2012) Asymmetry of neurodegenerative disease-related pathologies: a cautionary note. Acta Neuropathol 123(3):449A452. https://doi.org/10.1007/s00401-011-0936-6CrossRefPubMed

52.

Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90(5):1977A1981. https://doi.org/10.1073/pnas.90.5.1977CrossRefPubMedPubMedCentralADS

53.

Takemoto M, Yamashita T, Ohta Y, Tadokoro K, Omote Y, Morihara R, Abe K (2021) Cerebral microbleeds in patients with Parkinson’s disease and dementia with lewy bodies: comparison using magnetic resonance imaging and 99 mTc-ECD SPECT subtraction imaging. J Alzheimer’s Dis 80(1):331A335. https://doi.org/10.3233/jad-201495CrossRef

54.

Thal DR, Ghebremedhin E, Rub U, Yamaguchi H, Del Tredici K, Braak H (2002) Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol 61(3):282A293. https://doi.org/10.1093/jnen/61.3.282CrossRefPubMed

55.

Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58(12):1791A1800. https://doi.org/10.1212/WNL.58.12.1791CrossRefPubMed

56.

Thomas DX, Bajaj S, McRae-McKee K, Hadjichrysanthou C, Anderson RM, Collinge J (2020) Association of TDP-43 proteinopathy, cerebral amyloid angiopathy, and Lewy bodies with cognitive impairment in individuals with or without Alzheimer’s disease neuropathology. Sci Rep 10(1):1A9. https://doi.org/10.1038/s41598-020-71305-2CrossRef

57.

Tian J, Shi J, Bailey K, Mann DM (2003) Negative association between amyloid plaques and cerebral amyloid angiopathy in Alzheimer’s disease. Neurosci Lett 352(2):137A140. https://doi.org/10.1016/j.neulet.2003.08.048CrossRefPubMed

58.

Toledo JB, Gopal P, Raible K, Irwin DJ, Brettschneider J, Sedor S et al (2016) Pathological α-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology. Acta Neuropathol 131(3):393A409. https://doi.org/10.1007/s00401-015-1526-9CrossRefPubMed

59.

Vinters HV, Gilbert JJ (1983) Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke 14(6):924A928. https://doi.org/10.1161/01.str.14.6.924CrossRefPubMed

60.

Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP Jr (1991) Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol 30(5):637A649. https://doi.org/10.1002/ana.410300503CrossRefPubMed

61.

Walker L, McAleese KE, Thomas AJ, Johnson M, Martin-Ruiz C, Parker C et al (2015) Neuropathologically mixed Alzheimer’s and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol 129(5):729A748. https://doi.org/10.1007/s00401-015-1406-3CrossRefPubMed

62.

Walker L, Stefanis L, Attems J (2019) Clinical and neuropathological differences between Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies current issues and future directions. J Neurochem. https://doi.org/10.1111/jnc.14698CrossRefPubMed

63.

Xiong L, Davidsdottir S, Reijmer YD, Shoamanesh A, Roongpiboonsopit D, Thanprasertsuk S et al (2016) Cognitive profile and its association with neuroimaging markers of non-demented cerebral amyloid angiopathy patients in a stroke unit. J Alzheimer’s Dis 52(1):171A178. https://doi.org/10.3233/jad-150890CrossRef

64.

Xu D, Yang C, Wang L (2003) Cerebral amyloid angiopathy in aged Chinese: a clinico-neuropathological study. Acta Neuropathol 106(1):89A91. https://doi.org/10.1007/s00401-003-0706-1CrossRefPubMed

65.

Yamashiro K, Tanaka R, Hoshino Y, Hatano T, Nishioka K, Hattori N (2015) The prevalence and risk factors of cerebral microbleeds in patients with Parkinson’s disease. Parkinsonism Relat Disord 21(9):1076A1081. https://doi.org/10.1016/j.parkreldis.2015.06.019CrossRefPubMed

66.

Yu L, Boyle PA, Nag S, Leurgans S, Buchman AS, Wilson RS et al (2015) APOE and cerebral amyloid angiopathy in community-dwelling older persons. Neurobiol Aging 36(11):2946A2953. https://doi.org/10.1016/j.neurobiolaging.2015.08.008CrossRefPubMedPubMedCentral

67.

Zekry D, Duyckaerts C, Belmin J, Geoffre C, Moulias R, Hauw JJ (2003) Cerebral amyloid angiopathy in the elderly: vessel walls changes and relationship with dementia. Acta Neuropathol 106(4):367A373. https://doi.org/10.1007/s00401-003-0738-6CrossRefPubMed

Title: Prevalence, distribution, and severity of cerebral amyloid angiopathy differ between Lewy body diseases and Alzheimer’s disease
Authors: Lauren Walker
Harry Simpson
Alan J. Thomas
Johannes Attems
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Alzheimer's Disease
Alzheimer's Disease
Parkinson's Disease
Dementia
Dementia
Pathology
Published in: Acta Neuropathologica Communications / Issue 1/2024
Electronic ISSN: 2051-5960
DOI: https://doi.org/10.1186/s40478-023-01714-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prevalence, distribution, and severity of cerebral amyloid angiopathy differ between Lewy body diseases and Alzheimer’s disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Personalized identification and characterization of genome-wide gene expression differences between patient-matched intracranial and extracranial melanoma metastasis pairs

The genomic alterations in glioblastoma influence the levels of CSF metabolites

The cycad genotoxin methylazoxymethanol, linked to Guam ALS/PDC, induces transcriptional mutagenesis

Brain injury drives optic glioma formation through neuron-glia signaling

The Schwann cell-specific G-protein Gαo (Gnao1) is a cell-intrinsic controller contributing to the regulation of myelination in peripheral nerve system

Single-cell analysis of a progressive Rosai–Dorfman disease affecting the cerebral parenchyma: a case report